We have compiled a timeline to commemorate the 40th anniversary of the Journal of Antimicrobial Chemotherapy (JAC). The timeline highlights key milestones and articles in JAC’s history, including top cited, top downloaded and articles with high Altmetric scores. All articles featured in the timeline will be freely accessible until the 31st December 2016. Scroll right to start exploring.
The British Society for Antimicrobial Chemotherapy (BSAC) is formed with the intention of coordinating research into many new antimicrobial agents. Alasdair M. Geddes, Chairman of the first Editorial Board, looks back on the early years of BSAC and JAC.
J. D. Williams is JAC's first Editor-in-Chief.
The Journal of Antimicrobial Chemotherapy launches. The Journal sets out to cater to a broad church of disciplines involved in the development and use of antibiotics and related agents, attracting authors and readers from the BSAC and beyond. The Journal’s first editorial was written by the first Editor-in-Chief, J. D. Williams.
Ian Phillips of St Thomas’ Hospital, London takes over as the Journal’s Editor-in-Chief and introduces a new section in the first issue of each volume of the Journal, providing detailed guidance to authors.
Does administering antifungal drugs in conjunction with liposomes enhance therapeutic activity in rodents?
David Speller of the Bristol Royal Infirmary becomes JAC’s new Editor-in-Chief. He and his team “wish to increase the proportion of articles dealing with well-conducted clinical investigations, and to evoke a vigorous correspondence on antimicrobial matters”.
Roger Finch fulfils the role of JAC’s Editor-in-Chief.
“There are relatively few specific antifungal agents...for the treatment of systemic mycoses, yet the incidence of such infections, particularly of those caused by Candida species among immunocompromised patients, is generally considered to have become extremely high.”
Martin Wood becomes the new Editor-in-Chief of JAC.
JAC describes a clinical strain of methicillin-resistant Staphylococcus aureus (MRSA) with reduced susceptibility to vancomycin (MIC 8 mg/L).
